• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Skinovation Pharm

Skinovation Pharm

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Jessica Alba's Honest Co. to remove controversial ingredient from its products

    Jessica Alba's Honest Co. to remove controversial ingredient from its products

  2. Amazon Prime ‘Levels Up’: Introducing Twitch Prime

    Amazon Prime ‘Levels Up’: Introducing Twitch Prime

  3. Global Skin Lighteners Market Growth of 9.29% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Beiersdorf, Este Lauder, P&G - Research and Markets

    Global Skin Lighteners Market Growth of 9.29% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Beiersdorf, Este Lauder, P&G - Research and Markets

  4. Mölnlycke Health Care AB: Research Shows Use of Dressings Can Make Pressure Ulcer Prevention More Effective

    Mölnlycke Health Care AB: Research Shows Use of Dressings Can Make Pressure Ulcer Prevention More Effective

  5. Asia Pacific Multivitamin Market 2016 & Market Forecasts to 2022 - Research and Markets

    Asia Pacific Multivitamin Market 2016 & Market Forecasts to 2022 - Research and Markets

  6. More Than 30 Data Presentations at the World Union of Wound Healing Societies Congress Expand Body of Evidence for Acelity Portfolio

    More Than 30 Data Presentations at the World Union of Wound Healing Societies Congress Expand Body of Evidence for Acelity Portfolio

  7. Perfect365 Exposes Dirty Little Secret Cosmetics to Millions of Makeup Lovers

    Perfect365 Exposes Dirty Little Secret Cosmetics to Millions of Makeup Lovers

  8. Jeunesse® Selected as the People’s Choice for Favorite Consumer Products Company

    Jeunesse® Selected as the People’s Choice for Favorite Consumer Products Company

  9. Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1

    Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1

  10. UPDATE: How to navigate this ridiculous 'SpongeBob' stock market

    UPDATE: How to navigate this ridiculous 'SpongeBob' stock market

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.